Giulia Giorgetti

5PUBLICATIONS
51CO-AUTHORS
Molecular targetsPredictive and prognostic markersMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 29, 2026
A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models.

|Nov 17, 2025
Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma.

W Frank Lenoir, Michael R McKeown, Giulia Giorgetti

|May 02, 2025
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.

Giulia Giorgetti, Elena Maroto-Martin, Debora Soncini

|Dec 11, 2024
NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma.

Debora Soncini, Pamela Becherini, Francesco Ladisa

|Jun 11, 2024
Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.

Shuhui Deng, Sanika Derebail, Vera Joy Weiler

Pageof 1

Frequent Collaborators

2 joint publications

Anil Aktas Samur

2 joint publications

Francesco Ladisa

2 joint publications

Mariateresa Fulciniti

2 joint publications

Nikhil C Munshi